(Stroke. 2001;32:1020.)
© 2001 American Heart Association, Inc.
Original Contributions |
Use of Suppression Subtractive Hybridization for Differential Gene Expression in Stroke
Discovery of CD44 Gene Expression and Localization in Permanent Focal Stroke in Rats
From the Departments of Cardiovascular Sciences and General Pharmacology (Y.Z.), DuPont Pharmaceuticals Company, Wilmington, Del.
Correspondence to Xinkang Wang, PhD, Department of Cardiovascular Sciences, DuPont Pharmaceuticals Company, Experimental Station, E400/3420B, Wilmington, DE 19880-0400. E-mail xinkang.wang{at}dupontpharma.com
Background and Purpose—CD44 is a transmembrane glycoprotein involved in endothelial cell recognition, lymphocyte trafficking, and regulation of cytokine gene expression in inflammatory diseases. The present report describes the discovery of upregulated CD44 gene expression and its spatial and temporal distribution in the brain after focal stroke.
Methods—Rats were subjected to permanent occlusion of the middle cerebral artery (MCAO). Suppression subtractive hybridization (SSH) strategy was used to identify differentially expressed genes. Northern blotting and real-time polymerase chain reaction were used to evaluate the expression of CD44 and hyaluronan synthase 2 (HAS-2) mRNA. Western blotting and immunohistochemistry were used to examine CD44 expression and cellular distribution.
Results—CD44 upregulation after focal stroke was discovered by the SSH approach and confirmed by DNA sequencing. Northern blot using a pooled poly(A)+ RNA revealed 3 splice variants of CD44 mRNA, and their inducible expression started at 6 hours (5.3-fold increase over sham operation), peaked at 24 hours (28.6-fold increase), and persisted up to 72 hours (17.8-fold increase) after MCAO. A parallel induction profile of HAS-2 mRNA was observed in the ischemic brain tissue. The levels of CD44 were markedly elevated at 6 hours (1.8-fold increase over sham; n=3), 24 hours (2.9-fold, peak induction; P<0.01), and 72 hours (2.4-fold increase; P<0.05) after MCAO by means of Western analysis. Immunohistochemical and confocal microscopy confirmed that constitutive expression of CD44 is limited to microvessels in normal brain but is strongly induced after ischemia, where the immunoreactive signal mainly resided in endothelial cells and monocytes. Double-labeling immunohistochemistry demonstrated that a marked induction of CD44 in the ischemic lesion is dominantly located in microglia and a subset of macrophages.
Conclusions—The discovery of concomitant induction of CD44 and HAS-2 mRNA expression and the localization of CD44 in the microglia, macrophages, and microvessels of the ischemic brain tissue suggest that an active interaction between CD44 and hyaluronan may occur and play a role in the known inflammatory response and tissue remodeling after stroke.
Key Words: cerebral ischemia • cytokines • gene expression • inflammation
This article has been cited by other articles:
 |
|
 |
|
  J. Choi, A. M. Miller, M. J. Nolan, B. Y. J. T. Yue, S. T. Thotz, A. F. Clark, N. Agarwal, and P. A. Knepper Soluble CD44 Is Cytotoxic to Trabecular Meshwork and Retinal Ganglion Cells In Vitro Invest. Ophthalmol. Vis. Sci., January 1, 2005; 46(1): 214 - 222. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Shojaei, L. Gallacher, and M. Bhatia Differential gene expression of human stem progenitor cells derived from early stages of in utero human hematopoiesis Blood, April 1, 2004; 103(7): 2530 - 2540. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Wang, X. Li, L. Xu, Y. Zhan, S. Yaish-Ohad, J. A. Erhardt, F. C. Barone, and G. Z. Feuerstein Up-Regulation of Secretory Leukocyte Protease Inhibitor (SLPI) in the Brain after Ischemic Stroke: Adenoviral Expression of SLPI Protects Brain from Ischemic Injury Mol. Pharmacol., October 1, 2003; 64(4): 833 - 840. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. S. Baekkevold, M. Roussigne, T. Yamanaka, F.-E. Johansen, F. L. Jahnsen, F. Amalric, P. Brandtzaeg, M. Erard, G. Haraldsen, and J.-P. Girard Molecular Characterization of NF-HEV, a Nuclear Factor Preferentially Expressed in Human High Endothelial Venules Am. J. Pathol., July 1, 2003; 163(1): 69 - 79. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Wang, L. Xu, H. Wang, R. Grzanna, Y. Zhan, R. M. Knabb, J. M. Luettgen, T. A. Bozarth, R. A. Galemmo, P. C. Wong, et al. Inhibition of Factor Xa Reduces Ischemic Brain Damage After Thromboembolic Stroke in Rats Stroke, February 1, 2003; 34(2): 468 - 474. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Wang, H. Wang, L. Xu, D. J. Rozanski, T. Sugawara, P. H. Chan, J. M. Trzaskos, and G. Z. Feuerstein Significant Neuroprotection against Ischemic Brain Injury by Inhibition of the MEK1 Protein Kinase in Mice: Exploration of Potential Mechanism Associated with Apoptosis J. Pharmacol. Exp. Ther., January 1, 2003; 304(1): 172 - 178. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Wang, L. Xu, H. Wang, P. R. Young, M. Gaestel, and G. Z. Feuerstein Mitogen-activated Protein Kinase-activated Protein (MAPKAP) Kinase 2 Deficiency Protects Brain from Ischemic Injury in Mice J. Biol. Chem., November 8, 2002; 277(46): 43968 - 43972. [Abstract] [Full Text] [PDF]
|
|